Enzyme News and Research

RSS

Celladon announces completion of patient enrollment for Phase 2 CUPID clinical trial

Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon’s consulting and management organization with clinical expertise in the development of cardiovascular products and trials.

31 Aug 2009

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Boehringer Ingelheim today announced data from the landmark RE-LY® study - the largest atrial fibrillation (AF) outcomes trial ever conducted (18,113 patients in 44 countries worldwide) - presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine. Results show that dabigatran etexilate 150mg BID significantly reduces the risk of stroke and systemic embolism by 34% (p<0.001) in patients with atrial fibrillation compared to well-controlled warfarin without increasing the risk of major bleeding.

31 Aug 2009

Antibiotic functioning as an off switch being developed for gene therapy of Parkinson's disease

A common antibiotic can function as an "off switch" for a gene therapy being developed for Parkinson's disease, according to University of Florida researchers writing online in advance of September's Molecular Therapy.

29 Aug 2009

Enzymes could be targeted to kill dangerous pathogens

Researchers at Burnham Institute for Medical Research (Burnham), University of Texas Southwestern Medical Center and University of Maryland have demonstrated that an enzyme that is essential to many bacteria can be targeted to kill dangerous pathogens.

28 Aug 2009

NIH awards $3.5-million grant to Tay-Sachs Gene Therapy Consortium for research on fatal genetic disorders

In a victory for families who dug into their own pockets to fund new research, the National Institutes of Health has awarded a $3.5-million grant to the Boston-based Tay-Sachs Gene Therapy Consortium to prepare a gene therapy for human clinical trials in a bid to halt the fatal genetic disorder.

28 Aug 2009

TRAF6 protein can activate a cell signalling molecule associated with cancer

The mainstay immune system protein TRAF6 plays an unexpected, key role activating a cell signaling molecule that in mutant form is associated with cancer growth, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 28 edition of Science.

28 Aug 2009

$11.5 million grant to Mayo Clinic Cancer Center to translate research into treatments for women with ovarian cancer

Investigators at the Mayo Clinic Cancer Center have received a five-year, $11.5 million grant to translate research into treatments for women with ovarian cancer.

28 Aug 2009

AgaMatrix educates health care professionals and patients on the importance of blood glucose meter accuracy

AgaMatrix, Inc., the makers of WaveSense blood glucose meters, announced today their continued commitment to educate health care professionals and patients on the importance of blood glucose meter (BGM) accuracy for all patients.

28 Aug 2009

Chk1 and Fbx6 play an important role for the regulation of response to chemotherapy

Cell cycle checkpoints act like molecular tripwires for damaged cells, forcing them to pause and take stock. Leave the tripwire in place for too long, though, and cancer cells will press on regardless, making them resistant to the lethal effects of certain types of chemotherapy, according to researchers at the Salk Institute for Biological Studies.

28 Aug 2009

Fatostatin lowers the activity of genes associated with cholesterol synthesis

A small molecule earlier found to have both anti-fat and anti-cancer abilities works as a literal turnoff for fat-making genes, according to a new report in the August 28th issue of the journal Chemistry and Biology, a Cell Press journal.

27 Aug 2009

$201,339 grant offered to a professor for developing a database on enzyme functions

Since the advent of the Human Genome Project an explosion of data has sent the science world scrambling. There is a growing demand to fine-tune genomic codes, which list the "ingredients for life," but do not adequately explain how those ingredients function. A Rutgers University-Camden biochemist is addressing this knowledge gap through the creation of a database for quick "background checks" on all known enzyme functions. Thanks to a National Institute of Health grant, Peter Palenchar, an assistant professor of chemistry at Rutgers-Camden, will categorize decades-worth of scholarship on enzymes into a database, beginning with those that bind to molecules that contain adenosine.

27 Aug 2009

DermaStream continuous streaming therapy for healing bedsores and chronic ulcers

More than six million people in the U.S. suffer from persistent wounds -- open sores that never seem to heal or, once apparently healed, return with a vengeance. The bedridden elderly and infirm are prone to painful and dangerous pressure ulcers, and diabetics are susceptible to wounds caused by a lack of blood flow to the extremities.

27 Aug 2009

Patients with Phenylketonuria face increased risk of developing severe neurological complications

Genetic researchers at Children's Memorial Hospital, Chicago, are aggressively identifying adult patients who suffer from the genetic disorder, Phenylketonuria (PKU), and are presenting those findings at the 11th International Congress of Inborn Errors of Metabolism in San Diego, August 29 through September 2.

26 Aug 2009

Herbalscience research throws light on causes of allergic rhinitis

Most people might think of nettle as simply a common and aggressive weed that can sting and cause skin irritation. But nettle has also been used for hundreds of years to treat seasonal allergies and other inflammatory diseases, although the precise nature of its anti-inflammatory effect was unknown. Now, scientists with HerbalScience have identified specific bioactives in nettle leaf extracts that inhibit in vitro receptors and enzymes known to be key in generating symptoms of allergic rhinitis, or hay fever.

26 Aug 2009

Modest decline for hypertension drug industry over the next decade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite generic erosion of many branded agents -- most notably Novartis's Diovan -- the hypertension drug market will experience only modest decline over the next decade.

26 Aug 2009

Gates Foundation awards $4.8M grant for improving sanitation systems in developing world

The Bill & Melinda Gates Foundation recently awarded a $4.8 million grant to the London School of Hygiene and Tropical Medicine to study and improve sanitation systems in the developing world, the Seattle Times' blog, "The Business of Giving" reports.

26 Aug 2009

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business.

25 Aug 2009

Genome BC's research projects to determine efficient methods of liberating fermentable sugars from dead pine

In order to reduce the Province's greenhouse gas emissions, the BC Bioenergy Strategy is calling for greatly increased production of renewable biofuels such as ethanol, from biomass grown in BC. Two new research projects, largely funded by Genome BC, will help to answer these questions and unlock the valuable green energy found within BC's forests.

25 Aug 2009

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology.

25 Aug 2009

Malaysian biotechnology industry expected to grow by revenue at an average rate of 15 percent per year

Malaysia's plans for its biotechnology sector remain ambitious even with the recent global meltdown. By 2020 the government envisages this sector will employ up to 160,000 people and will contribute to 5% of Malaysia's GDP.

25 Aug 2009

Enzyme News and Research

Celladon announces completion of patient enrollment for Phase 2 CUPID clinical trial

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Antibiotic functioning as an off switch being developed for gene therapy of Parkinson's disease

Enzymes could be targeted to kill dangerous pathogens

NIH awards $3.5-million grant to Tay-Sachs Gene Therapy Consortium for research on fatal genetic disorders

TRAF6 protein can activate a cell signalling molecule associated with cancer

$11.5 million grant to Mayo Clinic Cancer Center to translate research into treatments for women with ovarian cancer

AgaMatrix educates health care professionals and patients on the importance of blood glucose meter accuracy

Chk1 and Fbx6 play an important role for the regulation of response to chemotherapy

Fatostatin lowers the activity of genes associated with cholesterol synthesis

$201,339 grant offered to a professor for developing a database on enzyme functions

DermaStream continuous streaming therapy for healing bedsores and chronic ulcers

Patients with Phenylketonuria face increased risk of developing severe neurological complications

Herbalscience research throws light on causes of allergic rhinitis

Modest decline for hypertension drug industry over the next decade

Gates Foundation awards $4.8M grant for improving sanitation systems in developing world

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Genome BC's research projects to determine efficient methods of liberating fermentable sugars from dead pine

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Malaysian biotechnology industry expected to grow by revenue at an average rate of 15 percent per year

Understanding the DNA Damage Response in Innate Immunity eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo